These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36573513)

  • 41. Dapagliflozin for heart failure: is it a class effect?
    Raj GM; Wyawahare M
    Future Cardiol; 2021 Mar; 17(2):355-361. PubMed ID: 32755319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
    Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
    Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus.
    Evans M; Morgan AR; Davies S; Beba H; Strain WD
    Age Ageing; 2022 Oct; 51(10):. PubMed ID: 36201329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.
    Shah KS; Fang JC
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():109-120. PubMed ID: 34516288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
    Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
    Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
    Kashiwagi A; Araki S; Maegawa H
    J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
    Liu T; Li R; Wang X; Gao X; Zhang X
    Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
    Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
    Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives.
    Jensen J; Omar M; Kistorp C; Gustafsson F; Køber L; Møller JE; Schou M
    Basic Clin Pharmacol Toxicol; 2022 Jul; 131(1):5-17. PubMed ID: 35510595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular benefit of SGLT2 inhibitors.
    Mohebi R; Januzzi JL
    Crit Rev Clin Lab Sci; 2022 May; 59(3):142-155. PubMed ID: 34784839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.
    Vardeny O
    Am J Med; 2020 Feb; 133(2):182-185. PubMed ID: 31494110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation.
    Di Fusco SA; Gronda E; Mocini E; Lucà F; Bisceglia I; De Luca L; Caldarola P; Cipriani M; Corda M; De Nardo A; Francese GM; Napoletano C; Navazio A; Riccio C; Roncon L; Tizzani E; Nardi F; Urbinati S; Valente S; Gulizia MM; Gabrielli D; Oliva F; Imperoli G; Colivicchi F
    Eur Heart J Suppl; 2022 May; 24(Suppl C):C272-C277. PubMed ID: 35602255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
    Al Hamed FA; Elewa H
    Clin Ther; 2020 Nov; 42(11):e242-e249. PubMed ID: 33008610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
    Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
    Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.